GRÜNWALD (dpa-AFX) - Business is still flourishing at pharmaceutical manufacturer Dermapharm after nine months. In the first three quarters, the SDax company benefited from the good performance of its subsidiary Arkopharma and increased demand for dietary supplements and herbal extracts. This enabled the Group to cushion the impact of the discontinuation of vaccine production for the Mainz-based manufacturer Biontech. According to Group figures released on Wednesday, turnover from January to September rose by 18 percent year-on-year to just under 867 million euros.

However, as two of the Group's segments are still struggling with declining earnings, earnings before interest, taxes, depreciation and amortization (adjusted EBITDA), which are decisive for the forecast, only climbed comparatively slightly by just under two percent to around 244 million euros. As a result, the corresponding adjusted margin fell by 4.5 percentage points to 28.1%. The Executive Board confirmed its forecast, which was specified in August, and continues to aim for the upper end of the target ranges for turnover and adjusted earnings./tav/mis